Novartis
Boehringer to slash 600 jobs in native Germany
September 24, 2014Manufacturing and Production, Research and Development, Sales and Marketing AMNOG, Boehringer, Germany, Novartis, cuts, mergers, staff
Boehringer Ingelheim is to cut around 600 of its staff in Germany as part of a drive to reduce costs …
Novartis heart drug sees stellar results
September 1, 2014Sales and Marketing Diovan, LCZ696, Novartis, failure, heart, valsartan
Novartis’ new heart pill has produced stellar results in helping patients with heart failure live longer, making it the first …
Biogen Idec hires from Novartis to head ALS
September 1, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Biogen IDEC, Novartis, als, donald johns
Biogen Idec has appointed Dr Donald Johns as the vice president of its amyotrophic lateral sclerosis (ALS) innovation hub unit. …
Novartis must drop vaccine price, says UK govt
August 5, 2014Medical Communications, Sales and Marketing Bexsero, Novartis, innoculation, meningococcal vaccine
Novartis will have to significantly lower the price of its meningococcal B vaccine if it wants a lucrative UK inoculation …
Novartis makes Alzheimer’s deal
July 16, 2014Research and Development, Sales and Marketing Alzheimer's, Genentech, Novartis, bai, epstein
Novartis is to collaborate with the Banner Alzheimer’s Institute (BAI) to test two of the Swiss company’s investigational anti-amyloid treatments. …
Novartis forms alliance with Google on ‘smart lens’
July 15, 2014Medical Communications, Sales and Marketing Alcon, Novartis, diabetes, e-health, google, smart lens, wearable
Novartis eye care division Alcon has struck a deal with Google to develop a ‘smart’ contact lens designed to help …
Novartis faces data fraud charges in Japan
July 3, 2014Medical Communications, Sales and Marketing Diovan, Japan, Novartis, data, fraud, heart, valsartan
Novartis is facing criminal charges in Japan over the alleged falsifying of data for its once big-selling heart drug Diovan. …
NICE U-turn on cancer drug despite price increase
June 27, 2014Sales and Marketing Cancer, Glivec, NHS, Novartis, gists
UK pricing watchdog NICE has performed a U-turn on Glivec (imatinib) by issuing new draft guidance recommending the drug, despite …
Ranbaxy’s Diovan copycat approved in US
June 27, 2014Manufacturing and Production, Sales and Marketing Diovan, FDA, Novartis, Ranbaxy, blood pressure, sun pharmaceuticals, valsartan
Ranbaxy has won approval for its copycat form of Novartis’ blockbuster blood pressure drug Diovan, as the Swiss firm finally …
Novartis back under microscope
June 23, 2014Medical Communications, Sales and Marketing Italy, Novartis, avastin, fraud, influenza, vaccines
Novartis is under the microscope yet again in Italy, with police visiting the company’s sites at Siena and Origgio in …
Novartis emphasises pharma growth
June 19, 2014Sales and Marketing Novartis, breezhaler, dermatology, heart failure, oncology, respiratory
Novartis is to grow its pharma business by focussing on five key areas and predicts that it will have 14 …
Novartis hires Merck president to lead oncology
June 3, 2014Medical Communications, Research and Development, Sales and Marketing Bruno Strigini, MSD, Merck, Novartis, oncology
Novartis has hired Merck’s president of Europe and Canada Bruno Strigini to be its president of oncology. The role was …
Italy eyes €1.2 billion pharma fine
May 30, 2014Sales and Marketing Novartis, Roche, avastin, off label, wet and
Italy’s health ministry says it is looking for €1.2 billion in damages from Roche and Novartis over claims that the …
Novartis pays $200m for eye technology
May 22, 2014Sales and Marketing Novartis, eye technology, fovista, ophthotech, wet and
Novartis has bought the rights to licence and commercialise a novel anti-PGDF therapy which it is currently trialling in Phase …
Latest content
FibroFind appoints Lee Borthwick as CEO
